Description: Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.
Home Page: www.cellivery.com
K·BIZ DMC Tower
Seoul,
121-904
South Korea
Phone:
82 2 6495 7866
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 74.5215 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |